NASC · Can B Corp
$0.01
At close · Sep 3
Going-concern doubt
— flagged Nov 19, 2024
Substantial doubt about the company's ability to continue as a going concern.
“These factors raise substantial doubt as to the Company's ability to continue as a going concern.”View the 10-Q filed Nov 19, 2024
Market Cap
$720,499
Shares
75.84M
NASC metrics
54 of 114 screener metrics currently available.
Market overview
2 metricsShare price
$0.01
Market cap
$720,499
Price action
19 metricsPrice change (1W)
-1.2%
Price change (30D)
-48.1%
Price change (3M)
-36.2%
Price change (6M)
-44.7%
Price change (YTD)
-48.1%
Price change (1Y)
-44.7%
Trailing year
Price change (5Y)
—
52-week high
$0.04
52-week low
$0.01
Change from 52-week high
-76.3%
Change from 52-week low
+22.1%
Annualized volatility
226.2%
Beta
0.4
RSI (14D)
42.3
Price vs SMA 50
-35.5%
Price vs SMA 200
-51.3%
Avg volume (3M)
62,569
Relative volume
0.5
Average dollar volume
$726
Company
3 metricsSector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Shares outstanding
75.84M
Valuation
12 metricsP / E (TTM)
0.1
Trailing earnings · reciprocal yield 843.4%
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
0.6×
reciprocal yield 170.3%
P / book
—
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
2.5
reciprocal yield 40.6%
Earnings yield
-2,185.2%
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
—
Profitability
9 metricsGross margin
-33.2%
Operating margin
-1,035.9%
Trailing 12 months
Net margin
-1,282.8%
Gross profit (TTM)
−$343,304
Operating profit (TTM)
−$10.71M
Net income (TTM)
−$13.26M
Trailing 12 months
Diluted EPS (TTM)
$0.07
FCF margin
—
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
-96.4%
Year over year
Net income growth YoY
—
Revenue (TTM)
$1.03M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+464.6%
Year over year · more shares
Revenue CAGR (3Y)
+8.0%
Revenue CAGR (5Y)
+26.4%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
—
Return on assets
-714.3%
Debt / equity
—
Current ratio
0.1
EBITDA (TTM)
−$10.02M
Free cash flow (TTM)
—
Quick ratio
0.1
Interest coverage
-4.2
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$7,879
Latest balance sheet
Cash & equivalents
$7,879
Total assets
$1.86M
Total debt
—
Cash flow & spend
7 metricsOperating cash flow (TTM)
$246,464
Capital expenditures (TTM)
$15,000
R&D (TTM)
—
SG&A (TTM)
—
Stock compensation (TTM)
—
R&D / revenue
—
Stock compensation / revenue
—
Ownership (13F)
3 metrics13F filers
—
13F filer change QoQ
—
Institutional ownership
—
Short interest
3 metricsShort interest
0.0%
Latest settlement · 1.0 days to cover
Days to cover
1.0d
Short-squeeze score
17 / 100
Insider activity
2 metricsNet insider buying (90D)
—
Insider-sentiment score
—
Risk flags
1 metricsGoing concern
Flagged